APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neurodegenerative Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025190 pages

Choose your research edition.

Industry ResearchNeurodegenerative Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Drugs Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Neurodegenerative Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neurodegenerative Drugs include TEVA, Sanofi, Novartis, Luye Pharma, Livzon Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Pfizer and Huahai Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neurodegenerative Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurodegenerative Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurodegenerative Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neurodegenerative Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Neurodegenerative Drugs Segment by Company

TEVA

Sanofi

Novartis

Luye Pharma

Livzon Pharmaceutical

Kanghong Pharmaceutical

Jingxin Pharmaceutical

Pfizer

Huahai Pharmaceutical

Hisun Pharmaceutical

Haisco Pharmaceutical

GlaxoSmithKline

Ark Pharmaceutical

Dongcheng Biochemicals

BORA PHARMACEUTICALS

UCB

Merck Serono

Boehringer Ingelheim

Biogen Idec

Neurodegenerative Drugs Segment by Type

NMDA

SSRIs

Dopamine Inhibitors

Neurodegenerative Drugs Segment by Application

Parkinson’s Disease

Amyotrophic Lateral Sclerosis

Huntington Disease

Alzheimer’s Disease

Neurodegenerative Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neurodegenerative Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Neurodegenerative Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Neurodegenerative Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Neurodegenerative Drugs Industry Trends Table 2. Neurodegenerative Drugs Industry Drivers Table 3. Neurodegenerative Drugs Industry Opportunities and Challenges Table 4. Neurodegenerative Drugs Industry Restraints Table 5. Global Neurodegenerative Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Neurodegenerative Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Neurodegenerative Drugs Sales by Manufacturers (Tons) & (2021-2026) Table 8. Global Neurodegenerative Drugs Sales Market Share by Manufacturers Table 9. Global Neurodegenerative Drugs Average Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 10. Global Neurodegenerative Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Neurodegenerative Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Neurodegenerative Drugs Manufacturers, Product Type & Application Table 13. Global Neurodegenerative Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Neurodegenerative Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of NMDA Table 17. Major Manufacturers of SSRIs Table 18. Major Manufacturers of Dopamine Inhibitors Table 19. Global Neurodegenerative Drugs Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 21. Global Neurodegenerative Drugs Sales by Type (2027-2032) & (Tons) Table 22. Global Neurodegenerative Drugs Sales Market Share by Type (2021-2026) Table 23. Global Neurodegenerative Drugs Sales Market Share by Type (2027-2032) Table 24. Global Neurodegenerative Drugs Revenue by Type 2021 VS 2025 VS 2032 (Tons) Table 25. Global Neurodegenerative Drugs Revenue by Type (2021-2026) & (Tons) Table 26. Global Neurodegenerative Drugs Revenue by Type (2027-2032) & (Tons) Table 27. Global Neurodegenerative Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Neurodegenerative Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Parkinson’s Disease Table 30. Major Manufacturers of Amyotrophic Lateral Sclerosis Table 31. Major Manufacturers of Huntington Disease Table 32. Major Manufacturers of Alzheimer’s Disease Table 33. Global Neurodegenerative Drugs Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 34. Global Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 35. Global Neurodegenerative Drugs Sales by Application (2027-2032) & (Tons) Table 36. Global Neurodegenerative Drugs Sales Market Share by Application (2021-2026) Table 37. Global Neurodegenerative Drugs Sales Market Share by Application (2027-2032) Table 38. Global Neurodegenerative Drugs Revenue by Application 2021 VS 2025 VS 2032 (Tons) Table 39. Global Neurodegenerative Drugs Revenue by Application (2021-2026) & (Tons) Table 40. Global Neurodegenerative Drugs Revenue by Application (2027-2032) & (Tons) Table 41. Global Neurodegenerative Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Neurodegenerative Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Neurodegenerative Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 44. Global Neurodegenerative Drugs Sales by Region (2021-2026) & (Tons) Table 45. Global Neurodegenerative Drugs Sales Market Share by Region (2021-2026) Table 46. Global Neurodegenerative Drugs Sales Forecasted by Region (2027-2032) & (Tons) Table 47. Global Neurodegenerative Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Neurodegenerative Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 49. North America Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 50. North America Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 51. Europe Neurodegenerative Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 52. Europe Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 53. Europe Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 54. Asia Pacific Neurodegenerative Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 55. Asia Pacific Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 56. Asia Pacific Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 57. South America, Middle East and Africa Neurodegenerative Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 58. South America, Middle East and Africa Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 59. South America, Middle East and Africa Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 60. Global Neurodegenerative Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Neurodegenerative Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Neurodegenerative Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Neurodegenerative Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Neurodegenerative Drugs Revenue Market Share by Region (2027-2032) Table 65. TEVA Company Information Table 66. TEVA Business Overview Table 67. TEVA Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. TEVA Neurodegenerative Drugs Product Portfolio Table 69. TEVA Recent Development Table 70. Sanofi Company Information Table 71. Sanofi Business Overview Table 72. Sanofi Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sanofi Neurodegenerative Drugs Product Portfolio Table 74. Sanofi Recent Development Table 75. Novartis Company Information Table 76. Novartis Business Overview Table 77. Novartis Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Novartis Neurodegenerative Drugs Product Portfolio Table 79. Novartis Recent Development Table 80. Luye Pharma Company Information Table 81. Luye Pharma Business Overview Table 82. Luye Pharma Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Luye Pharma Neurodegenerative Drugs Product Portfolio Table 84. Luye Pharma Recent Development Table 85. Livzon Pharmaceutical Company Information Table 86. Livzon Pharmaceutical Business Overview Table 87. Livzon Pharmaceutical Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 89. Livzon Pharmaceutical Recent Development Table 90. Kanghong Pharmaceutical Company Information Table 91. Kanghong Pharmaceutical Business Overview Table 92. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 94. Kanghong Pharmaceutical Recent Development Table 95. Jingxin Pharmaceutical Company Information Table 96. Jingxin Pharmaceutical Business Overview Table 97. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 99. Jingxin Pharmaceutical Recent Development Table 100. Pfizer Company Information Table 101. Pfizer Business Overview Table 102. Pfizer Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Pfizer Neurodegenerative Drugs Product Portfolio Table 104. Pfizer Recent Development Table 105. Huahai Pharmaceutical Company Information Table 106. Huahai Pharmaceutical Business Overview Table 107. Huahai Pharmaceutical Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 109. Huahai Pharmaceutical Recent Development Table 110. Hisun Pharmaceutical Company Information Table 111. Hisun Pharmaceutical Business Overview Table 112. Hisun Pharmaceutical Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 114. Hisun Pharmaceutical Recent Development Table 115. Haisco Pharmaceutical Company Information Table 116. Haisco Pharmaceutical Business Overview Table 117. Haisco Pharmaceutical Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 119. Haisco Pharmaceutical Recent Development Table 120. GlaxoSmithKline Company Information Table 121. GlaxoSmithKline Business Overview Table 122. GlaxoSmithKline Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. GlaxoSmithKline Neurodegenerative Drugs Product Portfolio Table 124. GlaxoSmithKline Recent Development Table 125. Ark Pharmaceutical Company Information Table 126. Ark Pharmaceutical Business Overview Table 127. Ark Pharmaceutical Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 129. Ark Pharmaceutical Recent Development Table 130. Dongcheng Biochemicals Company Information Table 131. Dongcheng Biochemicals Business Overview Table 132. Dongcheng Biochemicals Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio Table 134. Dongcheng Biochemicals Recent Development Table 135. BORA PHARMACEUTICALS Company Information Table 136. BORA PHARMACEUTICALS Business Overview Table 137. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio Table 139. BORA PHARMACEUTICALS Recent Development Table 140. UCB Company Information Table 141. UCB Business Overview Table 142. UCB Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. UCB Neurodegenerative Drugs Product Portfolio Table 144. UCB Recent Development Table 145. Merck Serono Company Information Table 146. Merck Serono Business Overview Table 147. Merck Serono Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Merck Serono Neurodegenerative Drugs Product Portfolio Table 149. Merck Serono Recent Development Table 150. Boehringer Ingelheim Company Information Table 151. Boehringer Ingelheim Business Overview Table 152. Boehringer Ingelheim Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio Table 154. Boehringer Ingelheim Recent Development Table 155. Biogen Idec Company Information Table 156. Biogen Idec Business Overview Table 157. Biogen Idec Neurodegenerative Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Biogen Idec Neurodegenerative Drugs Product Portfolio Table 159. Biogen Idec Recent Development Table 160. Key Raw Materials Table 161. Raw Materials Key Suppliers Table 162. Neurodegenerative Drugs Distributors List Table 163. Neurodegenerative Drugs Customers List Table 164. Research Programs/Design for This Report Table 165. Authors List of This Report Table 166. Secondary Sources Table 167. Primary Sources List of Figures Figure 1. Neurodegenerative Drugs Product Image Figure 2. Global Neurodegenerative Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurodegenerative Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurodegenerative Drugs Sales (2021-2032) & (Tons) Figure 5. Global Neurodegenerative Drugs Average Price (US$/Ton) & (2021-2032) Figure 6. Global Top 5 and 10 Neurodegenerative Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. NMDA Image Figure 9. SSRIs Image Figure 10. Dopamine Inhibitors Image Figure 11. Global Neurodegenerative Drugs Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Neurodegenerative Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Neurodegenerative Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Neurodegenerative Drugs Revenue by Type (2021 VS 2025 VS 2032) & (Tons) Figure 15. Global Neurodegenerative Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Neurodegenerative Drugs Revenue Market Share by Type (2021-2032) Figure 17. Parkinson’s Disease Image Figure 18. Amyotrophic Lateral Sclerosis Image Figure 19. Huntington Disease Image Figure 20. Alzheimer’s Disease Image Figure 21. Global Neurodegenerative Drugs Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 22. Global Neurodegenerative Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Neurodegenerative Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Neurodegenerative Drugs Revenue by Application (2021 VS 2025 VS 2032) & (Tons) Figure 25. Global Neurodegenerative Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Neurodegenerative Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 28. North America Neurodegenerative Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 30. Canada Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 31. Mexico Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 32. Europe Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 33. Europe Neurodegenerative Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 35. France Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 36. U.K. Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 37. Italy Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 38. Netherlands Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 39. Asia Pacific Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 40. Asia Pacific Neurodegenerative Drugs Sales Market Share by Country (2021-2032) Figure 41. China Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 42. Japan Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 43. South Korea Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 44. Southeast Asia Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 45. India Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 46. Australia Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 47. South America, Middle East and Africa Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 48. South America, Middle East and Africa Neurodegenerative Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 50. South Africa Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 51. Saudi Arabia Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 52. Turkey Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 53. Argentina Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 54. UAE Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 55. Egypt Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 56. Chile Neurodegenerative Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 57. Global Neurodegenerative Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Neurodegenerative Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Neurodegenerative Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Neurodegenerative Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Neurodegenerative Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Neurodegenerative Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Neurodegenerative Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Neurodegenerative Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Neurodegenerative Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • NMDA
  • SSRIs
  • Dopamine Inhibitors
Applications
  • Parkinson’s Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Alzheimer’s Disease
Companies covered
  • TEVA
  • Sanofi
  • Novartis
  • Luye Pharma
  • Livzon Pharmaceutical
  • Kanghong Pharmaceutical
  • Jingxin Pharmaceutical
  • Pfizer
  • Huahai Pharmaceutical
  • Hisun Pharmaceutical
  • Haisco Pharmaceutical
  • GlaxoSmithKline
  • Ark Pharmaceutical
  • Dongcheng Biochemicals
  • BORA PHARMACEUTICALS
  • UCB
  • Merck Serono
  • Boehringer Ingelheim
  • Biogen Idec

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurodegenerative Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurodegenerative Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Neurodegenerative Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Neurodegenerative Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Neurodegenerative Drugs Market Dynamics
  1. 2.1 Neurodegenerative Drugs Industry Trends
  2. 2.2 Neurodegenerative Drugs Industry Drivers
  3. 2.3 Neurodegenerative Drugs Industry Opportunities and Challenges
  4. 2.4 Neurodegenerative Drugs Industry Restraints
3 Neurodegenerative Drugs Market by Manufacturers
  1. 3.1 Global Neurodegenerative Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Neurodegenerative Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Neurodegenerative Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Neurodegenerative Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neurodegenerative Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Neurodegenerative Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Neurodegenerative Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neurodegenerative Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neurodegenerative Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neurodegenerative Drugs Tier 1, Tier 2, and Tier 3
4 Neurodegenerative Drugs Market by Type
  1. 4.1 Neurodegenerative Drugs Type Introduction
  2. 4.1.1 NMDA
  3. 4.1.2 SSRIs
  4. 4.1.3 Dopamine Inhibitors
  5. 4.2 Global Neurodegenerative Drugs Sales by Type
  6. 4.2.1 Global Neurodegenerative Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neurodegenerative Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Neurodegenerative Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Neurodegenerative Drugs Revenue by Type
  10. 4.3.1 Global Neurodegenerative Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neurodegenerative Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Neurodegenerative Drugs Revenue Market Share by Type (2021-2032)
5 Neurodegenerative Drugs Market by Application
  1. 5.1 Neurodegenerative Drugs Application Introduction
  2. 5.1.1 Parkinson’s Disease
  3. 5.1.2 Amyotrophic Lateral Sclerosis
  4. 5.1.3 Huntington Disease
  5. 5.1.4 Alzheimer’s Disease
  6. 5.2 Global Neurodegenerative Drugs Sales by Application
  7. 5.2.1 Global Neurodegenerative Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neurodegenerative Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Neurodegenerative Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Neurodegenerative Drugs Revenue by Application
  11. 5.3.1 Global Neurodegenerative Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neurodegenerative Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Neurodegenerative Drugs Revenue Market Share by Application (2021-2032)
6 Global Neurodegenerative Drugs Sales by Region
  1. 6.1 Global Neurodegenerative Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurodegenerative Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Neurodegenerative Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Neurodegenerative Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurodegenerative Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Neurodegenerative Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Neurodegenerative Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Neurodegenerative Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Neurodegenerative Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Neurodegenerative Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Neurodegenerative Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Neurodegenerative Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Neurodegenerative Drugs Revenue by Region
  1. 7.1 Global Neurodegenerative Drugs Revenue by Region
  2. 7.1.1 Global Neurodegenerative Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Neurodegenerative Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Neurodegenerative Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Neurodegenerative Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Neurodegenerative Drugs Revenue (2021-2032)
  8. 7.2.2 North America Neurodegenerative Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Neurodegenerative Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Neurodegenerative Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Neurodegenerative Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Neurodegenerative Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Neurodegenerative Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Neurodegenerative Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 TEVA
  2. 8.1.1 TEVA Company Information
  3. 8.1.2 TEVA Business Overview
  4. 8.1.3 TEVA Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 TEVA Neurodegenerative Drugs Product Portfolio
  6. 8.1.5 TEVA Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Neurodegenerative Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Neurodegenerative Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Luye Pharma
  20. 8.4.1 Luye Pharma Company Information
  21. 8.4.2 Luye Pharma Business Overview
  22. 8.4.3 Luye Pharma Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
  24. 8.4.5 Luye Pharma Recent Developments
  25. 8.5 Livzon Pharmaceutical
  26. 8.5.1 Livzon Pharmaceutical Company Information
  27. 8.5.2 Livzon Pharmaceutical Business Overview
  28. 8.5.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
  30. 8.5.5 Livzon Pharmaceutical Recent Developments
  31. 8.6 Kanghong Pharmaceutical
  32. 8.6.1 Kanghong Pharmaceutical Company Information
  33. 8.6.2 Kanghong Pharmaceutical Business Overview
  34. 8.6.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
  36. 8.6.5 Kanghong Pharmaceutical Recent Developments
  37. 8.7 Jingxin Pharmaceutical
  38. 8.7.1 Jingxin Pharmaceutical Company Information
  39. 8.7.2 Jingxin Pharmaceutical Business Overview
  40. 8.7.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
  42. 8.7.5 Jingxin Pharmaceutical Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Neurodegenerative Drugs Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Huahai Pharmaceutical
  50. 8.9.1 Huahai Pharmaceutical Company Information
  51. 8.9.2 Huahai Pharmaceutical Business Overview
  52. 8.9.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
  54. 8.9.5 Huahai Pharmaceutical Recent Developments
  55. 8.10 Hisun Pharmaceutical
  56. 8.10.1 Hisun Pharmaceutical Company Information
  57. 8.10.2 Hisun Pharmaceutical Business Overview
  58. 8.10.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
  60. 8.10.5 Hisun Pharmaceutical Recent Developments
  61. 8.11 Haisco Pharmaceutical
  62. 8.11.1 Haisco Pharmaceutical Company Information
  63. 8.11.2 Haisco Pharmaceutical Business Overview
  64. 8.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
  66. 8.11.5 Haisco Pharmaceutical Recent Developments
  67. 8.12 GlaxoSmithKline
  68. 8.12.1 GlaxoSmithKline Company Information
  69. 8.12.2 GlaxoSmithKline Business Overview
  70. 8.12.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
  72. 8.12.5 GlaxoSmithKline Recent Developments
  73. 8.13 Ark Pharmaceutical
  74. 8.13.1 Ark Pharmaceutical Company Information
  75. 8.13.2 Ark Pharmaceutical Business Overview
  76. 8.13.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
  78. 8.13.5 Ark Pharmaceutical Recent Developments
  79. 8.14 Dongcheng Biochemicals
  80. 8.14.1 Dongcheng Biochemicals Company Information
  81. 8.14.2 Dongcheng Biochemicals Business Overview
  82. 8.14.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
  84. 8.14.5 Dongcheng Biochemicals Recent Developments
  85. 8.15 BORA PHARMACEUTICALS
  86. 8.15.1 BORA PHARMACEUTICALS Company Information
  87. 8.15.2 BORA PHARMACEUTICALS Business Overview
  88. 8.15.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
  90. 8.15.5 BORA PHARMACEUTICALS Recent Developments
  91. 8.16 UCB
  92. 8.16.1 UCB Company Information
  93. 8.16.2 UCB Business Overview
  94. 8.16.3 UCB Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 UCB Neurodegenerative Drugs Product Portfolio
  96. 8.16.5 UCB Recent Developments
  97. 8.17 Merck Serono
  98. 8.17.1 Merck Serono Company Information
  99. 8.17.2 Merck Serono Business Overview
  100. 8.17.3 Merck Serono Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Merck Serono Neurodegenerative Drugs Product Portfolio
  102. 8.17.5 Merck Serono Recent Developments
  103. 8.18 Boehringer Ingelheim
  104. 8.18.1 Boehringer Ingelheim Company Information
  105. 8.18.2 Boehringer Ingelheim Business Overview
  106. 8.18.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Recent Developments
  109. 8.19 Biogen Idec
  110. 8.19.1 Biogen Idec Company Information
  111. 8.19.2 Biogen Idec Business Overview
  112. 8.19.3 Biogen Idec Neurodegenerative Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
  114. 8.19.5 Biogen Idec Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neurodegenerative Drugs Value Chain Analysis
  2. 9.1.1 Neurodegenerative Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neurodegenerative Drugs Production Mode & Process
  6. 9.2 Neurodegenerative Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neurodegenerative Drugs Distributors
  9. 9.2.3 Neurodegenerative Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst